Generation of Biological Samples Positive to Hydrochlorothiazide for Anti-doping Control

NCT04197622 | Completed Phase 1

• 1 other identifier: IMIMFTCL/HCTZ
• Study Type: interventional
• Target: 3
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Hydrochlorothiazide is a diuretic that inhibits the reabsorption of sodium and chloride in the renal tubules, thus increasing the excretion of water. The use of hydrochlorothiazide in athletes is prohibited by the World Anti-Doping Agency. Its fraudulent administration can lead to significant acute weight losses (body water reduction) and can mask the use of other doping substances, since it increases the urine volume and alters its pH (false negatives). The main degradation product of hydrochlorothiazide is 4-amino-6-chloro-1,3-benzenedisulfonamide (ACB). ACB is detectable in urine for a longer time and in a greater concentration than hydrochlorothiazide. This suggests that ACB may be an important marker for the detection of hydrochlorothiazide doping. Hypothesis: The oral administration of 12,5 mg of hydrochlorothiazide in healthy subjects allows generating detectable concentrations of the drug in urine. Positive urine samples will enable to identify analytical strategies for doping control. Objectives: Primary objective: To measure the concentrations of hydrochlorothiazide in urine for anti-doping control samples. Secondary objectives: To identify hydrochlorothiazide metabolites in urine. To explore the time window in which the drug or its metabolites can be detected in urine after administration. To assess safety and tolerability of the drug used. Methods: Phase I, open, non-randomized clinical trial, with a treatment condition (hydrochlorothiazide) administered in a single oral dose to 3 subjects.

Conditions

Healthy Volunteers

Keywords

Hydrochlorothiazide; Anti-doping control; Athletic performance

Outcome Measures

Primary Outcomes (6)

• Urine concentration of hydrochlorothiazide

  Concentration of hydrochlorothiazide in fraction-1 urine samples

  0-4 hours post-administration

• Urine concentration of hydrochlorothiazide

  Concentration of hydrochlorothiazide in fraction-2 urine samples

  4-8 hours post-administration

• Urine concentration of hydrochlorothiazide

  Concentration of hydrochlorothiazide in fraction-3 urine samples

  8-12 hours post-administration

• Urine concentration of hydrochlorothiazide

  Concentration of hydrochlorothiazide in fraction-4 urine samples

  12-24 hours post-administration

• Urine concentration of hydrochlorothiazide

  Concentration of hydrochlorothiazide in fraction-5 urine samples

  24-36 hours post-administration

• Urine concentration of hydrochlorothiazide

  Concentration of hydrochlorothiazide in fraction-6 urine samples

  36-48 hours post-administration

Secondary Outcomes (6)

• Urine concentration of hydrochlorothiazide metabolites

  0-4 hours post-administration

• Urine concentration of hydrochlorothiazide metabolites

  4-8 hours post-administration

• Urine concentration of hydrochlorothiazide metabolites

  8-12 hours post-administration

• Urine concentration of hydrochlorothiazide metabolites

  12-24 hours post-administration

• Urine concentration of hydrochlorothiazide metabolites

  24-36 hours post-administration

Study Arms (1)

Hydrochlorothiazide

EXPERIMENTAL

Subjects receive a single-dose treatment.Urine samples will be collected after administration (6 fractions: 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-administration).

Drug: Hydrochlorothiazide

Interventions

Hydrochlorothiazide DRUG

12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.

Hydrochlorothiazide

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male volunteers aged between 18 and 45 years.
• Able to understand and accept the trial procedures and able to sign an informed consent.
• History and physical examination that demonstrate not presenting organic or psychiatric disorders.
• ECG, blood and urine tests performed at screening should be within normal limits. Minor or punctual variations of these limits of normality are admitted if, in the opinion of the Principal Investigator, they have no clinical significance, do not pose a risk to the subject and do not interfere with the evaluation of the product in study. These variations and their non-relevance will be justified in writing specifically.
• Body mass index (weight/size\^2) between 19 and 26 kg/m2, and weight between 50 and 90 kg. Subjects with BMI \>26 kg/m2 may be included at the discretion of the Principal Investigator.

You may not qualify if:

• History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active substance or any of the excipients. History of serious adverse reactions to other medications.
• Subjects with contraindications to treatment with the study drug (according to Summary of Product Characteristics).
• Background or clinical evidence of psychiatric disorders, alcoholism, regular consumption of psychoactive drugs, drug abuse or addiction to other substances (except for nicotine). Smokers of more than 5 cigarettes/day will be excluded.
• Having participated in another clinical trial with medication in the three months prior to the start of the study.
• Having donated blood during the month prior to the start of the study.
• Having suffered an organic disease or major surgery in the three months prior to the start of the study.
• Background or clinical evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological, neurological, dermatological or other acute or chronic diseases that, in the opinion of the Principal Investigator or the collaborators designated by him, may pose a risk to the subjects, may interfere with the objectives of the study or may alter the pharmacokinetics of the drug.
• Have taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies or dietary supplements that, in the opinion of the Principal Investigator or the collaborators designated by him, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to the study sessions will not be exclusive if it is assumed that medication has been completely eliminated on the day of the experimental session.
• Consumption of more than 15 g of alcohol per day.
• Consumers of more than 3 coffees, teas, cola drinks and/or other stimulant drinks (xanthines) per day in the month prior to the start of the study.
• Being unable to understand the nature of the trial and the procedures requested to follow.
• Positive serology for hepatitis B, C or HIV.

Sponsors & Collaborators

• Parc de Salut Mar: lead

Study Sites (1)

IMIM (Hospital del Mar Medical Research Institute)

Barcelona, 08003, Spain

Location

MeSH Terms

Interventions

Hydrochlorothiazide

Intervention Hierarchy (Ancestors)

Chlorothiazide; Benzothiadiazines; Sulfonamides; Sulfones; Sulfur Compounds; Organic Chemicals; Thiazides; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Rafael de la Torre Fornell, Dr

  IMIM (Hospital del Mar Medical Research Institute)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2019
• First Posted: December 13, 2019
• Study Start: March 5, 2019
• Primary Completion: March 21, 2019
• Study Completion: March 21, 2019
• Last Updated: December 13, 2019

Record last verified: 2019-12

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)